STXS
Stereotaxis, Inc.
NYSE AmericanUSDEQUITY
Healthcare
DELAYED
Strong sell
-61/100
Last price
1.15
■ 0.00 (0.00%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
1.16
Prev close
1.15
Day high
1.15
Day low
1.12
Volume
337.02K
Market cap
$113.23M
P/E (TTM)
—
52W range
1.12 – 3.59
Day trading desk
Gap from prior close
+0.87%
Prior close 1.15
VWAP
1.13
+1.58% from price
Relative volume
0.41×
Quiet session
Session range
4.04%
1.12 – 1.16
Position in range
78%
Near session high
ATR (14D)
0.06
4.84% of price
Prior day high
1.21
PDH
Prior day low
1.13
PDL
Bid / ask spread
—
Quote not published
Session volume
332.99K
Avg 817.38K
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-8.13%
-10.0%
1M
-13.08%
-14.5%
3M
-35.06%
-38.5%
6M
-41.45%
-56.4%
YTD
-50.87%
-64.8%
1Y
-65.76%
-81.5%
3Y
-27.56%
-109.5%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
10 more panels on STXS open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
15.24M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Jul 1, 26 | SHAMIR NACHUM Director |
STOCK | 43.10K | $0 | Direct |
| Jul 1, 26 | MENAWAT ARUN SWARUP PH.D. Director |
STOCK | 43.10K | $0 | Direct |
| Jul 1, 26 | CURET MYRIAM MCADAMS Director |
STOCK | 43.10K | $0 | Direct |
| Jul 1, 26 | FISCHEL NATHAN Director and Beneficial Owner of more than 10% of a Class of Security |
STOCK | 43.10K | $0 | Direct |
| Jul 1, 26 | LEVIN ROSS B. Director |
STOCK | 43.10K | $0 | Direct |
| Jul 1, 26 | BENFER DAVID W Director |
STOCK | 43.10K | $0 | Direct |
| Jan 2, 26 | SHAMIR NACHUM Director |
STOCK | 46.95K | $0 | Direct |
| Jan 2, 26 | MENAWAT ARUN SWARUP PH.D. Director |
STOCK | 46.95K | $0 | Direct |
| Jan 2, 26 | FISCHEL NATHAN Director and Beneficial Owner of more than 10% of a Class of Security |
STOCK | 46.95K | $0 | Direct |
| Jan 2, 26 | LEVIN ROSS B. Director |
STOCK | 46.95K | $0 | Direct |
| Jan 2, 26 | CURET MCADAMS MYRIAM J Director |
STOCK | 46.95K | $0 | Direct |
| Jan 2, 26 | BENFER DAVID W Director |
STOCK | 46.95K | $0 | Direct |
| Nov 17, 25 | ISAAC PAUL J Director |
BUY | 30.00K | $66.60K | |
| Jul 1, 25 | SHAMIR NACHUM Director |
STOCK | 43.67K | $0 | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
BENFER DAVID W |
Director | 771.93K | Stock Award(Grant) |
CURET MCADAMS MYRIAM J |
Director | 392.06K | Stock Award(Grant) |
CURET MYRIAM MCADAMS |
Director | 435.16K | Stock Award(Grant) |
FISCHEL NATHAN |
Director and Beneficial Owner of more than 10% of a Class of Security | 14.40M | Stock Award(Grant) |
ISAAC PAUL J |
Director | — | Purchase |
LEVIN ROSS B. |
Director | 621.25K | Stock Award(Grant) |
MENAWAT ARUN SWARUP PH.D. |
Director | 1.04M | Stock Award(Grant) |
SHAMIR NACHUM |
Director | 179.33K | Stock Award(Grant) |
Fundamentals
Market cap$113.23M
Enterprise value$113.14M
Revenue (TTM)$30.07M
Gross profit$16.71M
EBITDA$-18.06M
Net income$-23.59M
EPS (TTM)$-0.24
Free cash flow$-8.83M
Total cash$10.49M
Total debt$5.17M
Book value / share$0.13
Shares outstanding100.20M
Float65.54M
Short % of float6.58%
Dividend yield0.00%
Beta (5Y)1.37
Valuation & profitability ratios
Trailing P/E—
Forward P/E-7.29
PEG ratio1.31
Price / sales—
Price / book9.04
EV / revenue3.76
EV / EBITDA-6.27
Gross margin55.57%
Operating margin-59.56%
Profit margin-74.24%
Return on equity-184.27%
Return on assets-25.38%
Debt / equity29.60
Current ratio1.42
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $32.38M | $26.92M | $26.77M | $28.15M | +20.3% |
| Operating revenue | $32.38M | $26.92M | $26.77M | $28.15M | +20.3% |
| Cost of revenue | $15.31M | $12.32M | $11.91M | $9.68M | +24.2% |
| Gross profit | $17.07M | $14.59M | $14.86M | $18.47M | +17.0% |
| Research & development | $9.38M | $9.76M | $10.27M | $10.56M | -3.9% |
| Selling, general & admin | $30.29M | $29.57M | $26.43M | $26.69M | +2.4% |
| Total operating expense | $39.18M | $39.33M | $36.70M | $37.25M | -0.4% |
| Operating income | -$22.11M | -$24.74M | -$21.84M | -$18.78M | +10.6% |
| Net interest income | $467.00K | $694.00K | $1.10M | $484.00K | -32.7% |
| Pre-tax income | -$21.64M | -$24.05M | -$20.71M | -$18.29M | +10.0% |
| Net income | -$21.64M | -$24.05M | -$20.71M | -$18.29M | +10.0% |
| Net income to common | -$22.91M | -$25.35M | -$22.06M | -$19.64M | +9.6% |
| Basic EPS | -0.25 | -0.30 | -0.27 | -0.26 | +16.7% |
| Diluted EPS | -0.25 | -0.30 | -0.27 | -0.26 | +16.7% |
| EBIT | -$22.11M | -$24.74M | -$21.84M | -$18.78M | +10.6% |
| EBITDA | -$20.56M | -$23.77M | -$21.24M | -$18.35M | +13.5% |
| Basic shares | 90.96M | 85.18M | 80.70M | 76.06M | +6.8% |
| Diluted shares | 90.96M | 85.18M | 80.70M | 76.06M | +6.8% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $13.42M | $12.22M | $19.82M | $8.59M | +9.9% |
| Cash & short-term investments | $13.42M | $12.22M | $19.82M | $28.43M | +9.9% |
| Accounts receivable | $5.85M | $3.82M | $3.82M | $5.09M | +52.9% |
| Inventory | $9.57M | $8.33M | $8.43M | $7.88M | +14.8% |
| Total current assets | $33.85M | $26.44M | $33.27M | $43.25M | +28.0% |
| Property, plant & equipment | $7.93M | $9.06M | $8.29M | $9.21M | -12.4% |
| Goodwill & intangibles | $10.19M | $11.12M | $0 | — | -8.4% |
| Total assets | $52.25M | $46.72M | $41.91M | $53.41M | +11.8% |
| Total current liabilities | $22.36M | $21.60M | $13.25M | $14.29M | +3.5% |
| Total debt | $5.44M | $6.01M | $5.49M | $5.86M | -9.5% |
| Total liabilities | $33.53M | $35.29M | $19.99M | $21.48M | -5.0% |
| Retained earnings | -$583.37M | -$561.73M | -$537.68M | -$516.97M | -3.9% |
| Shareholder equity | $18.72M | $11.43M | $21.92M | $31.93M | +63.8% |
| Working capital | $11.49M | $4.84M | $20.02M | $28.95M | +137.5% |
| Net tangible assets | $8.53M | $310.00K | $21.92M | $31.93M | +2,651.0% |
| Shares issued | 95.34M | 85.33M | 80.95M | 74.87M | +11.7% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$21.64M | -$24.05M | -$20.71M | -$18.29M | +10.0% |
| Depreciation & amortisation | $1.55M | $969.00K | $595.00K | $429.00K | +60.5% |
| Stock-based compensation | $9.85M | $10.26M | $10.62M | $10.58M | -4.0% |
| Change in working capital | -$5.62M | $2.50M | $612.00K | -$1.10M | -324.4% |
| Operating cash flow | -$13.69M | -$8.50M | -$9.14M | -$8.41M | -61.1% |
| Capital expenditure | -$93.00K | -$34.00K | -$366.00K | -$2.38M | -173.5% |
| Investing cash flow | -$93.00K | $74.00K | $19.77M | -$22.09M | -225.7% |
| Financing cash flow | $14.76M | $297.00K | $81.00K | $220.00K | +4,870.7% |
| Free cash flow | -$13.78M | -$8.53M | -$9.51M | -$10.79M | -61.5% |
| End cash position | $13.42M | $12.44M | $20.56M | $9.86M | +7.9% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $7.67M | $6.29M | $8.64M | $7.46M | $8.80M | +21.9% |
| Operating revenue | $7.67M | $6.29M | $8.64M | $7.46M | $8.80M | +21.9% |
| Cost of revenue | $3.18M | $2.50M | $4.32M | $3.36M | $4.22M | +27.5% |
| Gross profit | $4.49M | $3.79M | $4.33M | $4.10M | $4.58M | +18.2% |
| Research & development | $2.39M | $2.40M | $2.71M | $2.55M | $1.78M | -0.3% |
| Selling, general & admin | $6.66M | $7.38M | $7.27M | $8.11M | $7.27M | -9.7% |
| Total operating expense | $9.05M | $9.78M | $9.98M | $10.66M | $8.56M | -7.4% |
| Operating income | -$4.57M | -$5.98M | -$5.65M | -$6.56M | -$3.98M | +23.6% |
| Net interest income | $100.00K | $125.00K | $118.00K | $91.00K | $152.00K | -20.0% |
| Pre-tax income | -$4.47M | -$5.86M | -$5.53M | -$6.46M | -$3.83M | +23.8% |
| Net income | -$4.47M | -$5.86M | -$5.53M | -$6.46M | -$3.83M | +23.8% |
| Net income to common | -$4.78M | -$6.17M | -$5.85M | -$6.79M | -$4.14M | +22.5% |
| Basic EPS | -0.05 | -0.06 | -0.06 | -0.07 | -0.05 | +16.7% |
| Diluted EPS | -0.05 | -0.06 | -0.06 | -0.07 | -0.05 | +16.7% |
| EBIT | -$4.57M | -$5.98M | -$5.65M | -$6.56M | -$3.98M | +23.6% |
| EBITDA | -$4.16M | -$5.59M | -$5.25M | -$6.17M | -$3.58M | +25.5% |
| Basic shares | 100.03M | 98.89M | 95.97M | 92.01M | 87.95M | +1.2% |
| Diluted shares | 100.03M | 98.89M | 95.97M | 92.01M | 87.95M | +1.2% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $10.49M | $14.62M | $13.42M | $10.51M | $6.97M | -28.2% |
| Cash & short-term investments | $10.49M | $14.62M | $13.42M | $10.51M | $6.97M | -28.2% |
| Accounts receivable | $7.55M | $5.30M | $5.85M | $5.33M | $4.39M | +42.4% |
| Inventory | $12.52M | $10.49M | $9.57M | $10.15M | $9.61M | +19.3% |
| Total current assets | $37.99M | $36.03M | $33.85M | $26.66M | $21.90M | +5.4% |
| Property, plant & equipment | $7.54M | $7.72M | $7.93M | $8.21M | $8.49M | -2.3% |
| Goodwill & intangibles | $9.72M | $9.96M | $10.19M | $10.43M | $10.66M | -2.4% |
| Total assets | $55.58M | $54.03M | $52.25M | $45.59M | $41.17M | +2.9% |
| Total current liabilities | $26.80M | $23.09M | $22.36M | $20.37M | $20.75M | +16.1% |
| Total debt | $5.17M | $5.28M | $5.44M | $5.58M | $5.73M | -2.0% |
| Total liabilities | $38.10M | $34.43M | $33.53M | $34.05M | $34.42M | +10.7% |
| Retained earnings | -$593.70M | -$589.23M | -$583.37M | -$577.84M | -$571.37M | -0.8% |
| Shareholder equity | $17.48M | $19.60M | $18.72M | $11.53M | $6.75M | -10.8% |
| Working capital | $11.19M | $12.94M | $11.49M | $6.29M | $1.16M | -13.5% |
| Net tangible assets | $7.76M | $9.64M | $8.53M | $1.10M | -$3.91M | -19.6% |
| Shares issued | 97.94M | 97.49M | 95.34M | 91.09M | 86.00M | +0.5% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$4.47M | -$5.86M | -$5.53M | -$6.46M | -$3.83M | +23.8% |
| Depreciation & amortisation | $407.00K | $395.00K | $395.00K | $389.00K | $401.00K | +3.0% |
| Stock-based compensation | $1.61M | $2.11M | $2.45M | $2.50M | $2.37M | -23.8% |
| Change in working capital | -$1.86M | -$838.00K | -$1.64M | -$1.99M | -$2.63M | -121.8% |
| Operating cash flow | -$3.67M | -$3.44M | -$3.97M | -$4.20M | -$3.73M | -6.8% |
| Capital expenditure | -$64.00K | -$79.00K | -$70.00K | — | — | +19.0% |
| Investing cash flow | -$1.15M | -$79.00K | -$70.00K | $0 | -$23.00K | -1,349.4% |
| Financing cash flow | $695.00K | $4.72M | $6.95M | $7.74M | $34.00K | -85.3% |
| Free cash flow | -$3.74M | -$3.52M | -$4.04M | -$4.20M | -$3.76M | -6.2% |
| End cash position | $10.49M | $14.62M | $13.42M | $10.51M | $6.97M | -28.2% |
Options analytics
Put / call volume
0.15
Call-heavy session
Put / call open interest
—
Positioning, not flow
Max pain
2.50
+121.2% from spot
ATM implied vol
50.0%
Nearest strike to spot
Skew (10% OTM)
-50.0%
Calls bid over puts
Call volume
20
Contracts, this expiry
Put volume
3
Contracts, this expiry
Heaviest call OI
2.50
0 contracts
Heaviest put OI
2.50
0 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.05 | -0.05 | -7.1% |
| Mar 2026 | -0.05 | — | — |
| Dec 2025 | -0.07 | -0.06 | +7.7% |
| Sep 2025 | -0.06 | -0.07 | -16.7% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.06 | 2 | $9.60M | +28.6% |
| Next quarter | -0.05 | 2 | $10.73M | +24.2% |
| Current year | -0.21 | 2 | $34.33M | +6.0% |
| Next year | -0.16 | 2 | $45.67M | +33.0% |
Analyst targets & ownership
Mean target$3.00
High target$3.00
Low target$3.00
Implied upside160.87%
Analyst count3
ConsensusNONE
Strong buy / Buy1 / 2
Hold0
Sell / Strong sell0 / 0
Held by insiders15.20%
Held by institutions49.73%
Institutions holding139
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
1.22
-5.51% from price
SMA 20
1.27
-11.13% from price
SMA 50
1.34
-15.81% from price
SMA 100
1.54
-25.48% from price
SMA 200
1.83
-38.34% from price
EMA 12
1.22
-5.77% from price
EMA 26
1.28
-10.15% from price
EMA 50
1.36
-15.38% from price
RSI (14)
27.5
Oversold
MACD (12,26,9)
-0.06
Hist -0.01
ATR (14)
0.06
4.93% of price
Realised vol 30D
39.1%
Annualised
Bollinger upper
1.41
20, 2σ
Bollinger lower
1.13
20, 2σ
50 / 200 cross
Death
1.34 vs 1.83
Trend bias
Below 200
-38.34%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
1.75
More volatile than market
Correlation to SPY
0.43
Loosely linked
Realised vol 30D
39.1%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-68.3%
Peak to trough
Max drawdown 5Y
-83.5%
Peak to trough
ATR 14
0.06
4.93% of price
Beta (reported)
1.37
5Y monthly, from filing
Short interest
Shares short
5.58M
Prior 5.38M
Change vs prior
+3.6%
Shorts adding
% of float
6.58%
Normal
% of shares out
5.57%
Against total outstanding
Days to cover
10.5
Crowded exit
Float
65.54M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 27, 26 | Citizens | MAINTAINED | Market Outperform | Market Outperform |
| Aug 12, 26 | TD Cowen | MAINTAINED | Buy | Buy |
| May 13, 26 | Piper Sandler | MAINTAINED | Overweight | Overweight |
| Dec 16, 25 | Citizens | INITIATED | — | Market Outperform |
| Nov 12, 25 | Roth Capital | MAINTAINED | Buy | Buy |
| Mar 5, 24 | Lake Street | MAINTAINED | Buy | Buy |
| Mar 5, 24 | Roth MKM | MAINTAINED | Buy | Buy |
| Jan 10, 24 | Roth MKM | INITIATED | — | Buy |
| Mar 6, 23 | Piper Sandler | MAINTAINED | — | Overweight |
| Mar 6, 23 | Lake Street | MAINTAINED | — | Buy |
| Mar 6, 23 | B. Riley Securities | MAINTAINED | — | Buy |
| Nov 11, 22 | Cowen & Co. | MAINTAINED | — | Outperform |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay date—
Last split1096:1000
Split dateNov 4, 2013
SEC filings
Periodic Financial Reports
10-Q · 2026-08-12
Corporate Changes & Voting Matters
8-K · 2026-08-11
Corporate Changes & Voting Matters
8-K · 2026-07-16
Offering Registrations
S-3 · 2026-07-15
Corporate Changes & Voting Matters
8-K · 2026-07-09
Specialized Disclosure Report filed pursuant to Section 1502 of the Dodd-Frank Wall Street Reform and Consumer Protection Act relating to the use of conflict minerals (Rule 13p-1)
SD · 2026-05-29
Corporate Changes & Voting Matters
8-K · 2026-05-15
Periodic Financial Reports
10-Q · 2026-05-13
Headlines
Stereotaxis Emerging Digital, AI and Automation Capabilities to be Featured at Heart Rhythm Society’s HRX 2026
GlobeNewswire · 22d ago
Can AI Keep ISRG Ahead of Rising Robotic Surgery Competition?
Zacks · 24d ago
University of Szeged Celebrates Strongest First Month of Robotic Cardiology Program
GlobeNewswire · 35d ago
Stereotaxis (STXS) Q2 2026 Earnings Call Transcript
Motley Fool · 50d ago
ISRG's US Procedure Growth Slows: Is ACA Headwind a Temporary Concern?
Zacks · 57d ago
Stereotaxis, Inc. Q2 2026 Earnings Call Summary
Moby · 57d ago
Stereotaxis Q2 Earnings Call Highlights
MarketBeat · 57d ago
Stereotaxis Inc. (STXS) Reports Q2 Loss, Lags Revenue Estimates
Zacks · 57d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.